Market revenue in 2023 | USD 4,451.1 million |
Market revenue in 2030 | USD 7,416.6 million |
Growth rate | 7.6% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | BD, Danaher Corp, Koninklijke Philips NV, Qiagen NV, Thermo Fisher Scientific Inc, Myriad Genetics Inc, Argon Medical Devices, Roche Holding AG ADR, Hologic Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to breast cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 61.24% in 2023. Horizon Databook has segmented the Europe breast cancer diagnostics market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing prevalence of breast cancer, coupled with growing investments on R&D for diagnostics, is expected to drive the European market. According to The European Breast Cancer Coalition, in the WHO European region and EU-28, the estimated incidence of breast cancer in 2018 was 562,500 and 404,920, respectively, whereas mortality was 150,700 and 98,735, respectively. About 1 in 8 women aged 85 & below is expected to develop breast cancer in their lifetime.
However, the European economic crisis and the presence of uneven reimbursement policies act as market restraints. In 2017, a new regulation was established regarding diagnostics and medical devices in European countries and is likely to be implemented by 2022. The new regulation is estimated to present a more sustainable and robust framework for compliance of diagnostic devices.
Factors supporting growing incidence rate of breast cancer are also rising. For instance, obesity is responsible for ~33% of breast cancer cases. EU countries experience an overall rate of 10% to 30% for obesity, which is anticipated to increase the target population for breast cancer diagnostics in the coming years.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe breast cancer diagnostics market , including forecasts for subscribers. This continent databook contains high-level insights into Europe breast cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account